Source: International Congress 2018 – Eosinophils in airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. R. Hurst (London, United Kingdom), K. Kostikas (Basel, Switzerland), K. R. Chapman (ON, Canada), S. Frent (Timisoara, Romania), M. Larbig (Basel, Switzerland), R. Fogel (NJ, United States of America), T. Guerin (Dublin, Ireland), D. Banerji (NJ, United States of America), F. Patalano (Basel, Switzerland), P. Goyal (Basel, Switzerland), P. Pfister (Basel, Switzerland), J. A. Wedzicha (London, United Kingdom). Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study. 5387

Member's Comments

No comment yet.

Related content which might interest you: Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation Source: Eur Respir J, 53 (5) 1900235; 10.1183/13993003.00235-2019 Year: 2019 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Use of Inhaled corticosteroid (ICS)-containing regimen for COPD patients with high or low blood eosinophilia: A meta-analysis Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Statin use is associated with reduced mortality in COPD Source: Eur Respir J 2007; 29: 279-283 Year: 2007 How frequent is bronchodilator reversibility in patients with stable asthma bronchiale and chronic obstructive lung disease (COPD) receiving maintenance therapy? Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006 Duration of systemic corticosteroids treatment in COPD exacerbations Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD Source: Eur Respir J, 50 (5) 1701162; 10.1183/13993003.01162-2017 Year: 2017 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009